Cochrane · systematic review · CD009504
Bupropion for attention deficit hyperactivity disorder (ADHD) in adults
Verbeeck, W, Bekkering, GE, Van den Noortgate, W, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: Adults with ADHD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severity of ADHD (at study completion) WRAADDS scale (0 to 28), ADHD‐RS scale (0 to 54) or CAARS scale (0 to 48). On all scales, a higher score equates to more symptoms (at 6 weeks) | no estimate extracted | 3 studies · 129 participants | Low Downgraded: risk of bias, imprecision |
Achievement of significant clinical improvement (% participants) (at 6 to 10 weeks) | RR 1.5 [1.13, 1.99] | 4 studies · 315 participants | Low Downgraded: risk of bias, imprecision |
CGI ‐ Improvement scale (% participants achieving at least 1 or 2 on CGI) (at 6 to 10 weeks) | RR 1.78 [1.27, 2.5] | 5 studies · 337 participants | Low Downgraded: risk of bias, imprecision |
Number of participants withdrawn due to adverse events (at 6 to 10 weeks) | RR 1.2 [0.35, 4.1] | 3 studies · 253 participants | Low Downgraded: risk of bias, imprecision |